Cambridge Cognition Achieves 16% Revenue Increase to £5.0m in H1 2026, Expands Healthcare and Consumer Wellness Markets

Strong Double-Digit Revenue Growth and Entry into Healthcare Markets in H1 2026

Cambridge Cognition reported H1 2026 revenues of £5.0m, a 16% increase from £4.3m in H1 2025. This growth reflects ongoing demand for the company’s core CANTAB and Winterlight digital cognitive assessment platforms within scientific discovery and drug development sectors. Notably, H1 2026 includes the first significant revenue contribution of £0.1m from the newly established Healthcare and Consumer Wellness segments, marking a strategic diversification beyond traditional pharmaceutical and clinical research markets.

The order book stood at £16.1m as of 30 June 2026, compared to £16.4m a year earlier, indicating sustained customer engagement. New sales orders in H1 2026 totalled £6.0m, down 13% from £6.9m in H1 2025; management attributed this primarily to the timing of a £1.0m contract executed three days after the period end, excluded from H1 figures. Adjusting for this, order momentum remained stable. Contracted orders as of 30 June 2026 support full-year 2026 revenues of at least £10.0m, with six months left for further sales, underpinning material year-on-year growth and aligning with consensus forecasts of £11.35m for FY 2026.

Strategic Healthcare Partnerships and Global Expansion

In H1 2026, Cambridge Cognition secured three key commercial agreements enhancing its footprint in healthcare and consumer markets. A deal with a major European private healthcare group for CANTAB Pathway™ supports expansion across continental Europe’s healthcare systems, validating the clinical and commercial potential of the company’s cognitive assessment solutions in professional settings.

Additionally, a collaboration with Ōcura, a smart ring manufacturer, launched an institutional review board-approved brain health study examining links between rest, stress, behaviour, and cognitive function. This partnership highlights Cambridge Cognition’s capability to integrate its technology with consumer wearables, generating new data and health insights for clinical and consumer audiences. Furthermore, an agreement with Ivory to commercialise CANTAB Pathway™ in India marks entry into a significant emerging market with high demand for cognitive assessment tools.

£2.5m Placing to Accelerate Regulatory Approvals and Innovation

On 10 July 2026, Cambridge Cognition completed a £2.5m placing with targeted investors, allocating funds to three strategic initiatives: securing CE marking in Europe and FDA 510(k) clearance in the US, essential for marketing digital assessments as regulated medical devices; developing paediatric products to address early cognitive assessment needs in younger populations; and enhancing automated speech recognition (ASR) for the Winterlight platform to enable advanced linguistic and vocal biomarker analysis. These investments are expected to drive additional revenue growth from 2028 onwards.

Debt-Free Status and Strengthened Cash Position

Improved financial discipline was evident in H1 2026, with positive operational cash flow. Cash balances were £0.6m at 30 June 2026, down from £1.1m at December 2025 due to strategic debt reduction. Borrowings decreased to £0.2m from £0.9m, resulting in a net cash position of £0.4m. Post-period, the company fully repaid its £3.0m venture debt facility drawn in 2023, funded by the July placing, leaving Cambridge Cognition entirely debt-free. This enhances financial flexibility for product development, international growth, and working capital.

Adjusted EBITDA Loss Improves as Operating Leverage Develops

Adjusted EBITDA loss narrowed to £0.3m in H1 2026 from £0.4m in H1 2025, reflecting a £0.1m improvement alongside 16% revenue growth. This indicates emerging operating leverage as revenue scales without proportional cost increases. The business model benefits from modest marginal delivery costs for digital assessments and fixed costs spread over a growing revenue base. While near-term EBITDA margin gains may be moderated by investments in regulatory clearances, paediatric products, and ASR enhancements, these initiatives are expected to contribute to revenue acceleration from 2028.

CANTAB and Winterlight Platforms Drive Competitive Advantage

Cambridge Cognition’s competitive edge lies in its proprietary CANTAB and Winterlight platforms. CANTAB offers touchscreen cognitive assessments requiring minimal specialist administration, delivering objective results and supporting longitudinal monitoring. The CANTAB Pathway™ suite includes CANTAB One for brief assessments, CANTAB Insight™ for in-depth cognitive subdomain analysis, and CANTAB Plus with specialist modules for healthcare professionals addressing eight clinical indications including Parkinson’s, ADHD, multiple sclerosis, Huntington’s, schizophrenia, depression, and Alzheimer’s.

Winterlight is a voice-based cognitive assessment platform analysing speech patterns as biomarkers for neurological conditions, suitable for home use and clinical environments. Planned ASR enhancements aim to deepen linguistic analysis, differentiating Cambridge Cognition from competitors offering conventional or brief digital cognitive tests.

FY 2026 Guidance and Market Outlook

The Board expressed confidence in meeting FY 2026 market expectations. Consensus forecasts anticipate £11.35m in revenues and an adjusted loss before tax of £1.25m. Contracted orders of at least £10.0m and six months remaining for sales provide a credible path to meeting or exceeding revenue targets, reflecting a robust commercial pipeline and expanding demand across pharmaceutical, healthcare, and consumer segments. Achievement depends on successful contract execution and revenue recognition within calendar year 2026.

Regulatory Milestones as Medium-Term Growth Drivers

Investment in FDA 510(k) clearance and CE marking is a critical medium-term milestone. Regulatory approvals will enable deployment of Cambridge Cognition’s digital assessments within clinical workflows and hospital systems in major markets. The FDA 510(k) pathway offers an efficient route for moderate-risk devices, facilitating US market entry, which is substantially larger than current markets. CE marking will expand access to European healthcare systems. These approvals are expected within 12–24 months, with meaningful revenue impact anticipated from late 2027 or 2028, supporting medium-term growth and valuation uplift contingent on successful submissions.

Expansion into Consumer Health and Wellness for Revenue Diversification

The emergence of a Healthcare and Consumer Wellness revenue stream, contributing £0.1m in H1 2026, marks a strategic shift. Historically reliant on pharmaceutical and academic clients, Cambridge Cognition is broadening its addressable market and reducing dependence on cyclical pharmaceutical research. Partnerships with European healthcare groups, Ōcura, and Ivory validate commercial value in embedding cognitive assessments in consumer products and services. Consumer health represents a growing market, especially in affluent economies, where technology-enabled cognitive monitoring is in demand. Integration with wearables and telehealth platforms offers substantial market potential, though commercial models and margins may differ from pharmaceutical research.